vs
Side-by-side financial comparison of First Bancorp, Inc (FNLC) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $25.8M, roughly 1.3× First Bancorp, Inc). First Bancorp, Inc runs the higher net margin — 39.4% vs -299.9%, a 339.2% gap on every dollar of revenue. On growth, First Bancorp, Inc posted the faster year-over-year revenue change (17.5% vs 11.6%). Over the past eight quarters, First Bancorp, Inc's revenue compounded faster (18.1% CAGR vs 1.4%).
Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.
FNLC vs KPTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $34.1M |
| Net Profit | $10.2M | $-102.2M |
| Gross Margin | — | — |
| Operating Margin | 48.1% | -52.4% |
| Net Margin | 39.4% | -299.9% |
| Revenue YoY | 17.5% | 11.6% |
| Net Profit YoY | 39.7% | -232.0% |
| EPS (diluted) | $0.91 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $34.1M | ||
| Q3 25 | $24.5M | $44.0M | ||
| Q2 25 | $22.5M | $37.9M | ||
| Q1 25 | $21.8M | $30.0M | ||
| Q4 24 | $22.0M | $30.5M | ||
| Q3 24 | $20.5M | $38.8M | ||
| Q2 24 | $19.2M | $42.8M | ||
| Q1 24 | $18.5M | $33.1M |
| Q4 25 | $10.2M | $-102.2M | ||
| Q3 25 | $9.1M | $-33.1M | ||
| Q2 25 | $8.1M | $-37.3M | ||
| Q1 25 | $7.1M | $-23.5M | ||
| Q4 24 | $7.3M | $-30.8M | ||
| Q3 24 | $7.6M | $-32.1M | ||
| Q2 24 | $6.2M | $23.8M | ||
| Q1 24 | $6.0M | $-37.4M |
| Q4 25 | 48.1% | -52.4% | ||
| Q3 25 | 45.2% | -34.6% | ||
| Q2 25 | 43.7% | -64.3% | ||
| Q1 25 | 39.3% | -110.8% | ||
| Q4 24 | 39.5% | -102.4% | ||
| Q3 24 | 44.6% | -67.8% | ||
| Q2 24 | 38.8% | -65.7% | ||
| Q1 24 | 39.3% | -101.9% |
| Q4 25 | 39.4% | -299.9% | ||
| Q3 25 | 37.0% | -75.2% | ||
| Q2 25 | 35.8% | -98.2% | ||
| Q1 25 | 32.5% | -78.2% | ||
| Q4 24 | 33.1% | -100.8% | ||
| Q3 24 | 36.9% | -82.7% | ||
| Q2 24 | 32.1% | 55.6% | ||
| Q1 24 | 32.5% | -112.8% |
| Q4 25 | $0.91 | $-7.02 | ||
| Q3 25 | $0.81 | $-3.82 | ||
| Q2 25 | $0.72 | $-4.32 | ||
| Q1 25 | $0.63 | $-2.77 | ||
| Q4 24 | $0.66 | $-2.33 | ||
| Q3 24 | $0.68 | $-3.85 | ||
| Q2 24 | $0.55 | $-2.97 | ||
| Q1 24 | $0.54 | $-4.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $60.5M |
| Total DebtLower is stronger | $95.5M | — |
| Stockholders' EquityBook value | $283.1M | $-292.9M |
| Total Assets | $3.2B | $108.4M |
| Debt / EquityLower = less leverage | 0.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $60.5M | ||
| Q3 25 | — | $37.7M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | — | $38.8M | ||
| Q4 24 | — | $62.5M | ||
| Q3 24 | — | $72.8M | ||
| Q2 24 | — | $84.8M | ||
| Q1 24 | — | $30.6M |
| Q4 25 | $95.5M | — | ||
| Q3 25 | $95.5M | — | ||
| Q2 25 | $95.0M | — | ||
| Q1 25 | $70.0M | — | ||
| Q4 24 | $95.0M | — | ||
| Q3 24 | $95.0M | — | ||
| Q2 24 | $70.0M | — | ||
| Q1 24 | $70.0M | — |
| Q4 25 | $283.1M | $-292.9M | ||
| Q3 25 | $274.6M | $-269.3M | ||
| Q2 25 | $265.5M | $-238.9M | ||
| Q1 25 | $259.7M | $-205.9M | ||
| Q4 24 | $252.5M | $-186.0M | ||
| Q3 24 | $256.8M | $-159.6M | ||
| Q2 24 | $244.7M | $-132.1M | ||
| Q1 24 | $242.6M | $-169.0M |
| Q4 25 | $3.2B | $108.4M | ||
| Q3 25 | $3.2B | $96.2M | ||
| Q2 25 | $3.2B | $104.9M | ||
| Q1 25 | $3.2B | $127.7M | ||
| Q4 24 | $3.2B | $164.4M | ||
| Q3 24 | $3.1B | $189.5M | ||
| Q2 24 | $3.1B | $214.0M | ||
| Q1 24 | $3.0B | $204.5M |
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $37.8M | $-11.8M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 133.9% | — |
| Capex IntensityCapex / Revenue | 12.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 3.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $55.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.8M | $-11.8M | ||
| Q3 25 | $12.9M | $-5.9M | ||
| Q2 25 | $7.4M | $-18.7M | ||
| Q1 25 | $2.2M | $-39.0M | ||
| Q4 24 | $26.0M | $-25.8M | ||
| Q3 24 | $9.8M | $-19.5M | ||
| Q2 24 | $6.4M | $-38.5M | ||
| Q1 24 | $-1.5M | $-43.7M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $12.6M | — | ||
| Q2 25 | $7.2M | — | ||
| Q1 25 | $828.0K | — | ||
| Q4 24 | $24.6M | $-25.9M | ||
| Q3 24 | $9.6M | — | ||
| Q2 24 | $6.3M | — | ||
| Q1 24 | $-1.8M | $-43.9M |
| Q4 25 | 133.9% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 32.1% | — | ||
| Q1 25 | 3.8% | — | ||
| Q4 24 | 111.7% | -84.7% | ||
| Q3 24 | 47.0% | — | ||
| Q2 24 | 32.9% | — | ||
| Q1 24 | -9.8% | -132.6% |
| Q4 25 | 12.5% | 0.0% | ||
| Q3 25 | 1.2% | 0.0% | ||
| Q2 25 | 0.6% | 0.0% | ||
| Q1 25 | 6.2% | 0.0% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 0.3% | 0.0% | ||
| Q1 24 | 1.8% | 0.6% |
| Q4 25 | 3.72× | — | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 1.03× | -1.62× | ||
| Q1 24 | -0.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FNLC
Segment breakdown not available.
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
